Document:

Settlement Agreement - Sigma-Tau

 Exhibit 10.1 
 AGREEMENT 
 THIS AGREEMENT (“Agreement”), dated as of March 30, 2009, is made
by and between SciClone Pharmaceuticals, Inc., a Delaware corporation (“SciClone” or the “Company”), and the entities and natural persons listed on Schedule A hereto (collectively, the “Sigma-Tau
Group”) (each of the Company and the Sigma-Tau Group, a “Party” to this Agreement, and collectively, the “Parties”). 
 WHEREAS, as per the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on December 16, 2008 by the Sigma-Tau Group under the Securities Exchange Act of 1934
(the “Exchange Act”), the Sigma-Tau Group may be deemed to beneficially own shares of common stock of SciClone (the “Common Stock”) totaling, in the aggregate, 9,853,261 shares, or approximately 21.3% of the Common
Stock issued and outstanding on the date hereof; and 
 WHEREAS, SciClone and the Sigma-Tau Group have agreed that it is in
their mutual interests to enter into this Agreement. 
 NOW, THEREFORE, in consideration of the promises and the representations, warranties,
and agreements contained herein, and other good and valuable consideration, the Parties mutually agree as follows: 
 1.    Representations and Warranties of the Sigma-Tau Group. Each entity and natural person of the Sigma-Tau Group represents and warrants to SciClone that (a) this Agreement has been duly authorized,
executed and delivered by such entity or natural person, and is a valid and binding obligation, enforceable severally against such entity or natural person, as the case may be, in accordance with its terms, except as enforcement thereof may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles; (b) the execution of this Agreement, the
consummation of any of the transactions contemplated hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will not conflict with, or result in a breach or violation of the organizational documents of the
relevant signatory entity of the Sigma-Tau Group as currently in effect; (c) as of the date of this Agreement, the Sigma-Tau Group may be deemed to beneficially own in the aggregate 9,853,261 shares of Common Stock; and (d) the New
Appointees (as defined below) have advised the Sigma-Tau Group of their willingness to (1) serve as directors of SciClone if so elected and (2) provide any information about themselves as SciClone reasonably requests in order to comply
with its obligations under the federal securities laws. 
 2.    Representations and Warranties of SciClone. SciClone
hereby represents and warrants to the Sigma-Tau Group that (a) this Agreement has been duly authorized, executed and delivered by SciClone, and is a valid and binding obligation of SciClone, enforceable against SciClone in accordance with its
terms, including enforceability in respect of any violation by its directors, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or 

 
similar laws generally affecting the rights of creditors and subject to general equity principles; (b) the execution of this Agreement, the consummation
of any of the transactions contemplated hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will not (1) conflict with, result in a breach or violation of, constitute a default (or an event which
with notice or lapse of time or both could become a default) under or pursuant to, result in the loss of a material benefit or give any right of termination, amendment, acceleration or cancellation under, or result in the imposition of any lien,
charge or encumbrance upon any property or assets of SciClone or any of its subsidiaries pursuant to any law, any order of any court or other agency of government, SciClone’s Amended and Restated Certificate of Incorporation (as amended
July 16, 2003) (the “Restated Certificate”), SciClone’s Amended and Restated Bylaws (as amended December 17, 2007) (the “Bylaws”), or the terms of any indenture, contract, lease, mortgage, deed of
trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which SciClone is a party or bound or to which its property or assets is subject or (2) trigger any “change of control”
provisions in any agreement to which SciClone is a party; and (c) no consent, approval, authorization, license or clearance of, or filing or registration with, or notification to, any court, legislative, executive or regulatory authority or
agency is required in order to permit SciClone to perform its obligations under this Agreement, except for such as have been obtained. 
 3.    Directorships. 
 (a)    Prior to the time that SciClone mails its
definitive proxy statement for its 2009 annual stockholder meeting (the “2009 Annual Meeting”), but in any event no later than March 31, 2009, SciClone’s board of directors (the “Board”) and all applicable
committees of the Board shall take all necessary actions to (i) increase the size of the Board from seven (7) to ten (10) members and (ii) appoint Trevor Jones, Gregg Lapointe and Roberto Camerini (the “New
Appointees”) to fill the vacancies on the Board created by increasing its size to ten (10) members. 
 (b)    SciClone agrees that the Board and all applicable committees of the Board will nominate no more than eight (8) members for election to SciClone’s Board at the 2009 Annual Meeting. SciClone
further agrees that the Board and all applicable committees of the Board will take all actions necessary and appropriate to reduce the size of the Board to eight (8) members effective at the 2009 Annual Meeting. 
 (c)    SciClone agrees that the Board and all applicable committees of the Board will take all actions necessary and
appropriate to: 
  

 - 2 - 

 (i)    nominate the New Appointees, or any replacement
director appointed pursuant to Section 3(d) below, as applicable (the “Replacement Appointees,” and together with the remaining New Appointees, the “Sigma-Tau Directors”), for election to SciClone’s Board
at the 2009 Annual Meeting (other than in the case of such person’s refusal to serve or if such person has committed an act that would be grounds for removal from the Board for cause, in which case the Sigma-Tau Group will have the right to
designate and substitute another person or persons, subject to prompt reasonable evaluation and approval by the Nominating and Corporate Governance Committee of the Board or any successor committee (the “Nominating Committee”) in
good faith, which approval shall not be unreasonably withheld, with terms expiring at SciClone’s 2010 annual stockholder meeting (the “2010 Annual Meeting”); 
 (ii)    in addition to the Sigma-Tau Directors, nominate the following current members of the Board for
election to SciClone’s Board at the 2009 Annual Meeting (other than in the case of such person’s refusal or inability to serve or if such person has committed an act that would be grounds for removal from the Board for cause, in which case
SciClone will have the right to designate and substitute another person or persons, subject to prompt reasonable evaluation and approval by the Sigma-Tau Group in good faith, which approval shall not be unreasonably withheld, with terms expiring at
the 2010 Annual Meeting: Dean S. Woodman, Friedhelm Blobel, Jon S. Saxe, Ira D. Lawrence and Richard J. Hawkins (collectively, the “Incumbent Directors”); 
 (iii)    recommend, and reflect such recommendation in SciClone’s definitive proxy statement in connection
with the 2009 Annual Meeting, that the stockholders of SciClone vote to elect the Sigma-Tau Directors as directors of SciClone at the 2009 Annual Meeting; 
 (iv)    solicit and use its reasonable best efforts to obtain proxies in favor of the election of the Sigma-Tau Directors at the 2009 Annual Meeting, in the same manner as for the Incumbent
Directors; 
 (v)    ensure that the following Sigma-Tau Directors will be nominated to serve on
the committees of the Board identified below (or any successor committees): 
  

	 	(1)	Compensation Committee: Trevor Jones 

  

	 	(2)	Nominating and Corporate Governance Committee: Trevor Jones 

  

	 	(3)	Business Development Committee: Gregg Lapointe 

  

	 	(4)	Scientific Review Committee, which will be created promptly following the execution of this Agreement: Roberto Camerini; and 

  

 - 3 - 

 (vi)    approve, in accordance with the Rights Agreement dated
as of December 19, 2006 between SciClone and Mellon Investor Services LLC (the “Rights Agreement”), an increase in the number of shares of SciClone’s Common Stock beneficially owned by Sigma-Tau, together with all its
Affiliates and Associates (each as defined in the Rights Agreement) to permit the Sigma-Tau Directors to receive the equity compensation awards customarily offered to all independent directors of SciClone. 
 (d)    SciClone agrees that, while any of the Sigma-Tau Directors remains in office, if a Sigma-Tau Director resigns or is
otherwise unable to serve as a director or is removed for cause as a director, the Sigma-Tau Group will have the right to designate and substitute a person or persons for appointment to the Board as a replacement director, subject to evaluation and
approval by the Nominating Committee in good faith. The Nominating Committee will not unreasonably withhold acceptance of any replacement director(s) recommended by the Sigma-Tau Group and will make an acceptance determination no later than ten
(10) days after receiving notice from the Sigma-Tau Group of its designation of a replacement director. In the event the Nominating Committee does not accept a replacement director recommended by the Sigma-Tau Group, the Nominating Committee
must promptly notify the Sigma-Tau Group of the reasons for such failure to accept, and the Sigma-Tau Group will have the right to recommend additional replacement director(s) for consideration by the Nominating Committee. The Board will appoint
such replacement director to the Board no later than five (5) business days after the Nominating Committee’s recommendation of such replacement director. 
 (e)    Each of the Sigma-Tau Directors, upon election to the Board, will be governed by the same protections and obligations regarding confidentiality, conflicts of interests, fiduciary
duties, trading and disclosure policies and other governance guidelines, and shall have the same rights and benefits, including (but not limited to) with respect to insurance, indemnification, compensation and fees, as are generally applicable to
the non-employee directors of SciClone. 
 (f)    SciClone agrees that it shall hold the 2009 Annual Meeting no
later than June 15, 2009, and the 2010 Annual Meeting during the second week of June 2010, subject only to those reasonable delays, if any, which are necessitated by the selection by the Sigma-Tau Group of any Replacement Appointees.

 (g)    Except as provided in Section 3(a) above, SciClone agrees that prior to the 2010 Annual Meeting,
the Board and all applicable committees of the Board shall not (i) increase the size of the Board to more than eight (8) directors; (ii) increase the size of any committees of the Board; or (iii) take any other action to
materially limit or restrict the rights of or time allotted to its stockholders to nominate persons for election to the Board (including but not limited to by amending the Restated Certificate or Bylaws). 
  

 - 4 - 

 (h)    Any current SciClone director who does not continue as a director
following the 2009 Annual Meeting will not, without the prior consent of the Sigma-Tau Group, be invited to SciClone Board meetings or be compensated in any way for service as an advisory Board member or otherwise. 
 4.    Standstill Restrictions. 
 (a)    Subject to applicable law, including Section 13(d) and (g) of the Exchange Act, except as permitted pursuant to the terms of this Agreement, beginning on the date hereof and for a period ending
December 31, 2009, the Sigma-Tau Group shall not, and shall cause its Affiliates and Associates (as defined below) under its control or direction not to, in any manner, directly or indirectly: 
 (i)    solicit (as such term is used in the proxy rules of the SEC) proxies or consents to vote any securities
of SciClone, or make, or in any way participate in, any “solicitation” of any “proxy” within the meaning of Rule 14a-1 promulgated by the SEC under the Exchange Act to vote any shares of Common Stock with respect to any
matter, or become a “participant” in any “contested solicitation” for the election of directors with respect to SciClone (as such terms are defined or used in the Exchange Act and the rules promulgated thereunder), other than
solicitations or acting as a participant in support of all of SciClone’s nominees consistent with this Agreement; 
 (ii)    purchase or cause to be purchased or otherwise acquire or agree to acquire beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act) of any Common Stock or other
securities issued by SciClone; 
 (iii)    form, join or in any way participate in any
“group” (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to the Common Stock (other than a group comprised solely of the Sigma-Tau Group); 
 (iv)    deposit any Common Stock in any voting trust or subject any Common Stock to any arrangement or
agreement with respect to the voting of any Common Stock, other than any such voting trust, arrangement or agreement solely among the Sigma-Tau Group; 
 (v)    discuss publicly the circumstances surrounding the negotiation and execution of this Agreement. 
 (b)    Subject to applicable law, except as permitted pursuant to the terms of this Agreement, and provided that SciClone and its Board fully comply with their respective obligations
hereunder, beginning on the date hereof and for a period of one (1) year, the Sigma-Tau Group shall not, and shall cause its Affiliates and Associates (as defined below) under its control or direction not to, in any manner, directly or
indirectly: 
  

 - 5 - 

 (i)    seek, alone or in concert with others, (1) to call
a special meeting of SciClone stockholders, or (2) the removal of any member of the Board; or 
 (ii)    publicly disclose any request to amend, waive or terminate any provision of this Agreement. 
 (c)    Notwithstanding anything contained herein to the contrary, any member of the Sigma-Tau Group, and any Affiliate or Associate of any such member, shall be entitled to: 
 (i)    subject to Section 5, vote its shares in favor of the election of the Sigma-Tau Directors at the
2009 Annual Meeting and on any other proposal duly brought before the 2009 Annual Meeting, or otherwise vote as the Sigma-Tau Group determines in their sole discretion; 
 (ii)    disclose, publicly or otherwise, how it intends to vote or act with respect to any securities of the
Company, any stockholder proposal or other matter to be voted on by the stockholders of the Company and the reasons therefor; 
 (iii)    announce its opposition to any Board approved proposals related to a merger, acquisition, disposition of all or substantially all of the assets of SciClone or other business combination involving
SciClone; 
 (iv)    subject to Section 5, vote its shares of Common Stock in its discretion
on any matter submitted to a vote of the stockholders of the Company; 
 (v)    propose a slate of
nominees for election as directors and/or one or more proposal(s) for consideration or approval by stockholders at the 2010 Annual Meeting in order to comply with the advance notice provisions or other requirements of the Restated Certificate or the
Bylaws; 
 (vi)    in the event a special meeting is called by a stockholder of SciClone with
respect to the removal of directors, (A) vote all the shares of Common Stock held by the Sigma-Tau Group in favor of the Sigma-Tau Directors and (B) solicit proxies to vote against the removal of the Sigma-Tau Directors; and 
 (vii)    make any public announcement with respect to, and offer to effect, seek or propose (with or without
conditions) a merger, acquisition, disposition or other business combination involving SciClone. 
  

 - 6 - 

 (d)    Notwithstanding anything contained herein to the contrary, the
Sigma-Tau Directors shall be entitled to exercise their rights as members of the Board while serving as members of the Board. 
 (e)    As used in this Agreement, the terms “Affiliate” and “Associate” shall have the respective meanings set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act. 
 5.    Actions by the Sigma-Tau Group. 
 (a)    At the 2009 Annual Meeting, the Sigma-Tau Group shall vote all of the shares of Common Stock beneficially owned by it for (i) each of the Incumbent Directors and the Sigma-Tau
Directors and (ii) the ratification of the appointment of SciClone’s independent auditors. 
 (b)    Upon execution of this Agreement by the Parties, the Sigma-Tau Group shall withdraw the formal notice and nomination delivered to SciClone on December 31, 2008 and attached as Exhibit 12 to the
Schedule 13D filed with the SEC on January 2, 2009 by the Sigma-Tau Group, and shall not submit any additional proposals or nominations for election to the Board at the 2009 Annual Meeting. 
 6.    Termination. This Agreement shall terminate and the obligations of the Parties under this Agreement shall cease on the earlier of the
following (the “Termination Date”): 
 (a)    the 2010 Annual Meeting; 
 (b)    at the option of SciClone, upon a material breach by the Sigma-Tau Group of any obligation hereunder which has not been
cured within 14 days after the Sigma-Tau Group receives notice of such breach from SciClone; 
 (c)    at the
option of the Sigma-Tau Group, upon a material breach by SciClone of any obligation hereunder which has not been cured within 14 days after SciClone receives notice of such breach from the Sigma-Tau Group; 
 (d)    at the option of the Sigma-Tau Group, in the event the Board approves a material deviation from SciClone’s
anticipated research and development expenditure plans for 2009 and 2010 as previously provided in writing to the Sigma-Tau Group; or 
 (e)    at any time, upon the written consent of all of the Parties. 
  

 - 7 - 

 7.    Public Announcement. 
 (a)    SciClone shall promptly disclose the existence of this Agreement after its execution pursuant to a press release that is
mutually acceptable to the Parties, including a description of the material terms of this Agreement. Subject to applicable law, none of the Parties shall disclose the existence of this Agreement until the press release is issued. 
 (b)    The Sigma-Tau Group shall promptly prepare and file an amendment to its Schedule 13D (the “Schedule 13D
Amendment”) with respect to SciClone filed with the SEC on December 16, 2008, as subsequently amended, reporting the entry into this Agreement and amending applicable items to conform to its obligations hereunder. The 13D Amendment
shall be consistent with both the press release described above in Section 7(a) and the terms of this Agreement. The Sigma-Tau Group shall provide SciClone with reasonable opportunity to review and comment on the Schedule 13D Amendment prior to
the filing, and shall consider in good faith any changes proposed by SciClone. 
 (c)    SciClone shall promptly
file a current report on Form 8-K (the “Form 8-K”) with the SEC, reporting the entry into this Agreement. The Form 8-K shall be consistent with both the press release described above in Section 7(a) and the terms of this
Agreement. SciClone shall provide the Sigma-Tau Group with reasonable opportunity to review and comment on the Form 8-K prior to the filing, and shall consider in good faith any changes proposed by the Sigma-Tau Group. 
 8.    Remedies. 
 (a)    Each of the Parties acknowledges and agrees that a breach or threatened breach by any Party may give rise to irreparable injury inadequately compensable in damages, and accordingly each Party shall be
entitled to injunctive relief to prevent a breach of the provisions hereof and to enforce specifically the terms and provisions hereof in any state or federal court having jurisdiction, in addition to any other remedy to which such aggrieved Party
may be entitled to at law or in equity. 
 (b)    In the event a Party institutes any legal action to enforce such
Party’s rights under, or recover damages for, breach of this Agreement, the prevailing party or parties in such action shall be entitled to recover from the other party or parties all costs and expenses, including but not limited to reasonable
attorneys’ fees, court costs, witness fees, disbursements and any other expenses of litigation or negotiation incurred by such prevailing party or parties. 
  

 - 8 - 

 9.    Notices. Any notice or other communication required or permitted to be given under this
Agreement will be sufficient if it is in writing, sent to the applicable address set forth below (or as otherwise specified by a Party by notice to the other Parties in accordance with this Section 9) and delivered personally or sent by
recognized overnight courier, postage prepaid, and will be deemed given (a) when so delivered personally, or (b) if sent by recognized overnight courier, one day after the date of sending. A copy of any such notice or other communication
shall also be sent by electronic mail to the email addresses separately notified. 
 If to SciClone: 
 SciClone Pharmaceuticals, Inc. 
 950 Tower
Lane 
 Foster City, CA 94404 
 Attention: Friedhelm Blobel 
 Telephone: (650) 358-3456 
 Facsimile: (650) 358-3469 
 with a copy (which shall not
constitute notice to SciClone) to: 
 DLA Piper 
 2000 University Avenue 
 East Palo Alto, California 94303 
 Attention: Henry Lesser, Esq. 
 Telephone:
(650) 833-2000 
 Facsimile: (650) 833-2001 
 If to the Sigma-Tau Group: 
 Sigma-Tau Finanziaria, S.p.A. 
 Corporate Legal Department 
 Via Sudafrica, 20

 Rome, Italy 00144 
 Attention:
Stefano Marino 
     Fabio Amabile 
 Telephone: +39 06 91393971 
 Facsimile: +39 06 91393980 
 with a copy (which shall not constitute notice to the Sigma-Tau Group) to: 
 Negri-Clementi, Toffoletto, Montironi & Soci 
 via Agnello, 12 
 20121 Milano, Italy 
 Attention: Pietro
Maria Tantalo 
 Telephone: +39 02 72551.1 
 Facsimile: +39 02 72551.501 
  

 - 9 - 

 Orrick, Herrington & Sutcliffe LLP 
 666 Fifth Avenue 
 New York, New York 10103

 Attention: Howard L. Shecter, Esq. 
 Telephone: (212) 506-5155 
 Facsimile: (212) 506-5151 
 10.    Entire Agreement. This Agreement constitutes the entire agreement between the Parties pertaining to the subject matter hereof
and supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions of the Parties in connection with the subject matter hereof. 
 11.    Counterparts; Facsimile. This Agreement may be executed in any number of counterparts and by the Parties in separate counterparts, and signature pages may be delivered by facsimile, each of which when so
executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. 
 12.    Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 
 13.    Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware, without regard to choice of law principles that
would compel the application of the laws of any other jurisdiction. 
 14.    Severability. In the event one or more of the
provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and the Parties agree to
negotiate in good faith to adapt any such invalid, illegal or unenforceable provision, its application and/or this Agreement to the extent necessary to render this Agreement valid and enforceable in a manner that most closely and practicably
respects the original intent of the Parties. 
 15.    Successors and Assigns. This Agreement shall not be assignable by any of
the Parties. This Agreement, however, shall be binding on successors of the Parties. 
 16.    Amendments. This Agreement may not
be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by all of the Parties. 
  

 - 10 - 

 17.    Further Action. Each Party agrees to execute such additional reasonable documents, and
to do and perform such reasonable acts and things necessary or proper to effectuate or further evidence the terms and provisions of this Agreement. 
 [Signature page(s) to follow.] 
  

 - 11 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first above written.

  

			
	 SCICLONE PHARMACEUTICALS, INC.

		
	 By:
	  	 /s/ Friedhelm Blobel

	 Name:
	  	Friedhelm Blobel
	 Title:
	  	CEO and President

  

 - 12 - 

 THE SIGMA-TAU GROUP: 
  

							
	 SIGMA-TAU FINANZIARIA S.P.A.

				
	 By:
	  	 /s/ Ugo Di Francesco
	  		 	 /s/ Paolo Cavazza

	 Name:
	  	Ugo Di Francesco	  		 	PAOLO CAVAZZA
	 Title:
	  	Executive Vice President and CEO	  		 	
	
	 DEFIANTE FARMACEUTICA S.A.

				
	 By:
	  	 /s/ Paulo Viegas
	  		 	 /s/ Claudio Cavazza

	 Name:
	  	Paulo Viegas	  		 	CLAUDIO CAVAZZA
	 Title:
	  	Director	  		 	
	
	 APTAFIN S.P.A.

				
	 By:
	  	 /s/ Maurizio Terenzi
	  		 	
	 Name:
	  	Maurizio Terenzi	  		 	
	 Title:
	  	Managing Director	  		 	
	
	 CHAUMIERE-CONSULTADORIA E
 SERVICOS, SOCIEDADE
 UNIPESSOAL, LDA

				
	 By:
	  	 /s/ Joao Jose de Freitas Rodrigues
	  		 	
	 Name:
	  	Joao Jose de Freitas Rodrigues	  		 	
	 Title:
	  	Director	  		 	

  

 - 13 - 

 Schedule A 
 The Sigma-Tau Group 
 SIGMA-TAU FINANZIARIA S.P.A. 
 DEFIANTE FARMACEUTICA S.A. 
 APTAFIN S.P.A. 
 CHAUMIERE-CONSULTADORIA E SERVICOS, SOCIEDADE UNIPESSOAL, LDA 
 PAOLO
CAVAZZA 
 CLAUDIO CAVAZZA 
  

 - 14 -Zadaxin Agreement - Sigma-Tau Industrie Farmaceutiche Reunite SpA

 Exhibit 10.2 
 [Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Letterhead] 
 Sede: Viale Shakespeare, 47 – 00144 Roma 
 tel. +39 06 592.64.43 – +39 06 592.66.00 
 Stabilimento: Via Pontina km
30,400 
 00040 Pomezia (RM) Italia – tel. +39 06 9139 
 Pomezia, March 30, 2009 
 SciClone Pharmaceuticals, Inc. 
 950 Tower Lane 
 Foster City, CA 94404 
 Attention: Friedhelm Blobel 
 Dear Sirs: 
 Re:    (1) Expanded and Amended Thymosin Alpha 1 License, Distributorship and Supply Agreement signed by and between SciClone Pharmaceuticals International Ltd (“SPIL”) and Sigma-Tau Industrie Farmaceutiche
Riunite S.p.A. (“STI”) on March 3, 2000 as amended (collectively, the “Thymosin Alpha License Agreement”); and (2) Other Business Matters pertaining to Thymosin Alpha 1 for the malignant melanoma indication.

 The undersigned hereby agree that, upon execution hereof: 
 (1) SciClone Pharmaceuticals, Inc. (“SCLN”), with the approval of its Board of Directors, will cause SPIL, under the Thymosin Alpha 1 License Supply Agreement, to grant STI the rights, (i) to lead all future development
activities for Thymosin Alpha 1 (as defined in the Thymosin Alpha License Agreement) with respect to Hepatitis C Virus indications in the Territory as defined in the Thymosin Alpha License Agreement, at STI’s costs; provided that if SPIL’s
non-European interests will be materially affected by any negotiations in which STI participates then SPIL will have the right to participate in those negotiations, and (ii) to meet, correspond, and otherwise interact with the European
regulatory agencies responsible for granting any approval necessary for the development of Thymosin Alpha 1 for the treatment of the Hepatitis C Virus regarding such development and any matters related thereto. STI will keep SPIL appropriately
informed of the status of activities conducted by STI under this paragraph (1). 
 (2) SCLN (which term, for purposes of this paragraph (2), refers
to SPIL as to the development and commercialization of Thymosin Alpha 1 outside the United States) will work together with STI, at their respective cost, to find one or more third parties (each, a “Third Party”) willing to fund
further development and commercialization activities for Thymosin Alpha 1 in the United States and Europe (other than Italy, which is addressed in the final sentence of this paragraph) with respect to the malignant melanoma 

 
indication. SCLN and STI will cooperate in developing appropriate mutually acceptable licensing or other agreements (which will provide for the sharing of
profits arising therefrom under a formula to be mutually agreed among SCLN, STI and the applicable Third Party) to provide (whether by sublicense under the Thymosin Alpha License Agreement or otherwise) the applicable data and rights for such
development and commercialization to the applicable Third Party. SCLN and STI will keep one another appropriately informed of their respective discussions with potential Third Parties and will have the right to participate in those discussions that
affect their respective interests. For the avoidance of doubt, STI shall retain its exclusive license under the Thymosin Alpha License Agreement, or any other terms which may be agreed upon by the parties in good faith to compensate Sigma-Tau’s
possible waiver to its rights for European countries other than Italy, to (i) obtain and maintain any marketing authorizations necessary to market, use, distribute and sell Thymosin Alpha 1 in Italy and (ii) market, use, distribute and
sell Thymosin Alpha 1 in Italy also with respect to the malignant melanoma indication. 

			
	 SIGMA-TAU INDUSTRIE
 FARMACEUTICHE
RIUNITE SpA

		
	 By:
	 	 /s/ Ugo Di Francesco

	 Name:
	 	Ugo Di Francesco
	 Title:
	 	Vice President and CEO

 For Acceptance: 

			
	SCICLONE PHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ Friedhelm Blobel

	 Name:
	 	Friedhelm Blobel
	 Title:
	 	CEO and President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]